Skip to main content

Table 2 The baseline characteristics of 316 AML patients

From: Association of genetic polymorphisms in genes involved in Ara-C and dNTP metabolism pathway with chemosensitivity and prognosis of adult acute myeloid leukemia (AML)

Characteristics Totality, n (%) Median (range)
Gender 361  
 Male 196 (54.3%)  
 Female 165 (45.7%)  
Age 361 43 (16–76) years
FAB classification
 M1 19 (5.3%)  
 M2 193 (53.5%)  
 M4 63 (17.5%)  
 M5 75 (20.8%)  
 M6 6 (1.7%)  
 Undefined 5 (1.4%)  
WBC 356 (98.6%) 14.7 (0.4–426.0), × 109/L
LDH 341 (94.5%) 363 (17–5853), U/L
BM blast % 348 (96.4%) 71% (17–99%)
RBC 356 (98.6%) 2.19 (0.67–4.98), × 1012/L
Hemoglobin 356 (98.6%) 72 (27–149), g/L
Platelets 356 (98.6%) 34 (2–546), × 109/L
Neutrophil 356 (98.6%) 2.2 (0.0–340.3), × 109/L
Risk stratifications
 Low risk 71 (19.7%)  
 Intermediate risk 187 (51.8%)  
 High risk 78 (21.6%)  
 Undefined 25 (6.9%)  
FLT3-ITD mutation
 Positive 42 (11.6%)  
 Negative 294 (81.4%)  
 Unknown 25 (6.9%)  
NPM1 mutation
 Positive 67 (18.6%)  
 Negative 269 (74.5%)  
 Unknown 25 (6.9%)  
CEBPA mutation
 Positive 50 (13.9%)  
 Negative 286 (79.2%)  
 Unknown 25 (6.9%)  
Karyotype
 Normal 255 (70.6%)  
 Abnormal 84 (23.3%)  
 Unknown 22 (6.1%)  
Allo-HCT
 Yes 64 (17.7%)  
 No 297 (82.3%)  
CR after two courses of induction therapy
 Yes 205 (56.8%)  
 No 120 (33.2%)  
 Not evaluated 36 (10.0%)  
Chemotherapy regimens
 MA 125 (34.6%)  
 IA 86 (23.8%)  
 TA 47 (13.0%)  
 DA 31 (8.6%)  
 CAG 52 (14.4%)  
 Other regimens 20 (5.5%)  
  1. FAB French–Britain–American, WBC white blood cell, LDH lactate dehydrogenase, BM bone marrow, RBC red blood cell, Allo-SCT allogeneic hematopoietic stem cell transplantation, CR complete remission, THP pirarubicin, MA Ara-C + mitoxantrone, IA Ara-C + idarubicin, TA Ara-C + THP, DA Ara-C + daunorubicin, CAG Ara-C + aclarubicin + G-CSF